Targeting endoplasmic reticulum protein transport: A novel strategy to kill malignant B cells and overcome fludarabine resistance in CLL

Blood

Volumn 107, Issue 1, 2006, Pages 222-231

  Carew, Jennifer S ^a   Nawrocki, Steffan T ^a   Krupnik, Yelena V ^a   Dunner Jr , Kenneth ^a   McConkey, David J ^a   Keating, Michael J ^a   Huang, Peng ^a  

^a UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

APRIL PROTEIN; BREFELDIN A; FLUDARABINE; PROTEIN P53; SECRETORY PROTEIN; VASCULOTROPIN;

APOPTOSIS; ARTICLE; B LYMPHOCYTE; CANCER SURVIVAL; CELL DEATH; CELL KILLING; CELL SWELLING; CHRONIC LYMPHATIC LEUKEMIA; CONTROLLED STUDY; ENDOPLASMIC RETICULUM; ENZYME ACTIVATION; HUMAN; HUMAN CELL; PRIORITY JOURNAL; PROTEIN SECRETION; PROTEIN TARGETING; PROTEIN TRANSPORT; SENSITIVITY ANALYSIS; SIGNAL TRANSDUCTION;

EID: 30144437016     PISSN: 00064971     EISSN: 00064971     Source Type: Journal    
DOI: 10.1182/blood-2005-05-1923     Document Type: Article

References (83)

1. Caligaris-Cappio F, Hamblin TJ. B-cell chronic lymphocytic leukemia: a bird of a different feather. J Clin Oncol. 1999;17:399-408.
2. Kitada S, Zapata JM, Andreeff M, Reed JC. Bryostatin and CD40-ligand enhance apoptosis resistance and induce expression of cell survival genes in B-cell chronic lymphocytic leukaemia. Br J Haematol. 1999;106:995-1004.
3. Gottardi D, Alfarano A, De Leo AM, et al. In leukemic CD5+ B cells the expression of BCL-2 gene family is shifted toward protection from apoptosis. Br J Haematol. 1996;94:612-618.
4. Kitada S, Andersen J, Akar S, et al. Expression of apoptosis-regulating proteins in chronic lymphocytic leukemia: correlations with in vitro and in vivo chemoresponses. Blood. 1998;91:3379-3389.
5. Munzert G, Kirchner D, Stobbe H, et al. Tumor necrosis factor receptor-associated factor 1 gene overexpression in B-cell chronic lymphocytic leukemia: analysis of NF-kappa B/Rel-regulated inhibitors of apoptosis. Blood. 2002;100:3749-3756.
6. Bannerji R, Kitada S, Flinn IW, et al. Apoptotic-regulatory and complement-protecting protein expression in chronic lymphocytic leukemia: relationship to in vivo rituximab resistance. J Clin Oncol. 2003;21:1466-1471.
7. Moyshynska O, Sankaran K, Pahwa P, Saxena A. Prognostic significance of a short sequence insertion in the MCL-1 promoter in chronic lymphocytic leukemia. J Natl Cancer Inst. 2003;96:673-682.
8. Saxena A, Viswanathan S, Moyshynska O, Tandon P, Sankaran K, Sheridan DP. Mcl-1 and Bcl-2/Bax ratio are associated with treatment response but not with Rai stage in B-cell chronic lymphocytic leukemia. Am J Hematol. 2004;75:22-33.
9. Carew JS, Zhou Y, Albitar M, Carew JD, Keating MJ, Huang P. Mitochondrial DNA mutations in primary leukemia cells after chemotherapy: clinical significance and therapeutic implications. Leukemia. 2003;17:1437-1447.
10. Carew JS, Nawrocki ST, Xu RH, et al. Increased mitochondrial biogenesis in primary leukemia cells: the role of endogenous nitric oxide and impact on sensitivity to fludarabine. Leukemia. 2004;18:1934-1940.
11. Zhou Y, Hileman EO, Plunkett W, Keating MJ, Huang P. Free radical stress in chronic lymphocytic leukemia cells and its role in cellular sensitivity to ROS-generating anticancer agents. Blood. 2003;101:4098-4104.
12. Kay NE, Hamblin TJ, Jelinek DF, et al. Chronic lymphocytic leukemia. Hematology (Am Soc Hematol Educ Program). 2002:193-213.
13. Bannerji R, Byrd JC. Update on the biology of chronic lymphocytic leukemia. Curr Opin Oncol. 2000;12:22-29.
14. Rubartelli A, Sitia R, Zicca A, Grossi CE, Ferrarini M. Differentiation of chronic lymphocytic leukemia cells: correlation between the synthesis and secretion of immunoglobulins and the ultrastructure of the malignant cells. Blood. 1983;62:495-504.
15. Rubartelli A, Sitia R, Grossi CE, Ferrarini M. Maturation of chronic lymphocytic leukemia B cells: correlation between the capacity of responding T-cell factors in vitro and the stage of maturation reached in vivo. Clin Immunol Immunopathol. 1985;34:296-303.
16. Ferri KF, Kroemer G. Organelle-specific initiation of cell death pathways. Nat Cell Biol. 2001;3:E255-E263.
17. Rao RV, Castro-Obregon S, Frankowski H, et al. Coupling endoplasmic reticulum stress to the cell death program: an Apaf-1-independent intrinsic pathway. J Biol Chem. 2002;277:21836-21842.
18. Rutkowski DT, Kaufman RJ. A trip to the ER: coping with stress. Trends Cell Biol. 2004;14:20-28.
19. Kadowaki H, Nishitoh H, Ichijo H. Survival and apoptosis signals in ER stress: the role of protein kinases. J Chem Neuroanat. 2004;28:93-100.
20. Phillips LR, Wolfe TL, Malspeis L, Supko JG. Analysis of brefeldin A and the prodrug breflate in plasma by gas chromatography with mass selective detection. J Pharm Biomed Anal. 1998;16:1301-1309.
21. Developmental Therapeutics Program, National Cancer Institute. http://dtp.nci.nih.gov/docs/dtp_search.html. Accessed May 1, 2005.
22. Donaldson JG, Kahn RA, Lippincott-Schwartz J, Klausner RD. Binding of ARF and beta-COP to Golgi membranes: possible regulation by a trimeric G protein. Science. 1991;254:1197-1199.
23. Donaldson JG, Cassel D, Kahn RA, Klausner RD. ADP-ribosylation factor, a small GTP-binding protein, is required for binding of the coatamer protein beta-COP to Golgi membranes. Proc Natl Acad Sci U S A. 1992;89:6408-6412.
24. Donaldson JG, Finazzi D, Klausner RD. Brefeldin A inhibits Golgi membrane-catalyzed exchange of guanine nucleotide onto ARF protein. Nature. 1992;360:350-352.
25. Helms JB, Rothman JE. Inhibtion by brefeldin A of a Golgi membrane enzyme that catalyzes exchange of guanine nucleotide bound to ARF. Nature. 1992;360:352-354.
26. Orci L, Palmer DJ, Ravazzola M, Perrelet A, Amherdt M, Rothman JE. Budding from Golgi membranes requires the coatamer complex of nonclathrin coar proteins. Nature. 1993;362:648-652.
27. Fujiwara T, Oda K, Yokota S, Takatsuki A, Ikehara Y. Brefeldin A causes disassembly of the Golgi complex and accumulation of secretory proteins in the endoplasmic reticulum. J Biol Chem. 1988;263:18545-18552.
28. Huang P, Robertson LE, Wright S, Plunkett W. High molecular weight DNA fragmentation: a critical event in nucleoside analogue-induced apoptosis in leukemia cells. Clin Cancer Res. 1995;9:1005-1013.
29. Tsukada N, Burger JA, Zvaifler NJ, Kipps TJ. Distinctive features of "nurselike" cells that differentiate in the context of chronic lymphocytic leukemia. Blood. 2002;99:1030-1037.
30. Pelicano H, Feng L, Zhou Y, et al. Inhibition of mitochondrial respiration: a novel strategy to enhance drug-induced apoptosis in human leukemia cells by a reactive oxygen species-mediated mechanism. J Biol Chem. 2003;278:37832-37839.
31. Muller HK, Bucana CD, Kripke ML, Cox PA, Saijo S, Strickland FM. Ultraviolet irradiation of murine skin alters cluster formation between lymph node dendritic cells and specific T lymphocytes. Cell Immunol. 1994;157:263-276.
32. Nawrocki ST, Sweeney-Gotsch B, Takamori R, McConkey DJ. The proteasome inhibitor bortezomib enhances the activity of docetaxel in orthotopic human pancreatic tumor xenografts. Mol Cancer Ther. 2004;3:59-70.
33. Glassman AB, Hayes KJ. The value of fluorescence in situ hybridization in the diagnosis and prognosis of chronic lymphocytic leukemia. Cancer Genet Cytogenet. 2005;158:88-91.
34. Danhauser L, Plunkett W, Lilliemark J, Gandhi V, Iacoboni S, Keating MJ. Comparison between the plasma and intracellular pharmacology of 1-beta-D-arabinofuranocytosine and 9-beta-D-arabinofuranosyl-2-fluoroadenine 5′-monophosphate in patients with relapsed leukemia. Leukemia. 1987;1:638-643.
35. Danhauser L, Plunkett W, Keating M, Cabanillas F. 9-beta-D- arabinofuranosyl-2-fluoroadenine 5′-monophosphate pharmacokinetics in plasma and tumor cells of patients with relapsed leukemia and lymphoma. Cancer Chemother Pharmacol. 1986;18:145-152.
36. Gandhi V, Kemena A, Keating MJ, Plunkett W. Cellular pharmacology of fludarabine triphosphate in chronic lymphocytic leukemia cells during fludarabine therapy. Leuk Lymphoma. 1993;10:49-56.
37. Gandhi V, Plunkett W. Cellular and clinical pharmacology of fludarabine. Clin Pharamacokinet. 2002;41:93-103.
38. Ulmer JB, Palade GE. Effects of Brefeldin A on the Golgi complex, endoplasmic reticulum and viral envelope glycoproteins in murine erythroleukemia cells. Eur J Cell Biol. 1991;54:38-54.
39. Mancini M, Machamer CE, Roy S, et al. Caspase-2 is localized at the Golgi complex and cleaves golgin-160 during apoptosis. J Cell Biol. 2000;149:603-612.
40. Lassus P, Opitz-Araya X, Lazebnik Y. Requirement for caspase-2 in stress-induced apoptosis before mitochondrial permeabilization. Science. 2002;297:1352-1354.
41. Read SH, Baliga BC, Ekert PG, Vaux DL, Kumar S. A novel Apaf-1-independent putative caspase-2 activation complex. J Cell Biol. 2002;159:739-745.
42. Tinel A, Tschopp J. The PID Dosome, a protein complex implicated in activation of caspase-2 in response to genotoxic stress. Science. 2004;304:843-846.
43. Robertson JD, Gogvadze V, Kropotov A, Vakifahmetoglu H, Zhivotovsky B, Orrenius S. Processed caspase-2 can induce mitochondria-mediated apoptosis independently of its enzymatic activity. EMBO Rep. 2004;5:643-648.
44. Baliga BC, Read SH, Kumar S. The biochemical mechanism of caspase-2 activation. Cell Death Differ. 2004;11:1234-1241.
45. Enoksson M, Robertson JD, Gogvadze V, et al. Caspase-2 permeabilizes the outer mitochondrial membrane and disrupts the binding of cytochrome c to anionic phospholipids. J Biol Chem. 2004;279:49575-49578.
46. Gass JN, Gunn KE, Sriburi R, Brewer JW. Stressed out B cells? Plasma cell differentiation and the unfolded protein response. Trends Immunol. 2004;25:17-24.
47. Chen H, Trewecke AT, West DC, et al. In vitro and in vivo production of vascular endothelial growth factor by chronic lymphocytic leukemia cells. Blood. 2000;96:3181-3187.
48. Aguayo A, Kantarjian H, Manshouri T, et al. Angiogenesis in acute and chronic leukemias and myelodisplastic syndromes. Blood. 2000;96:2240-2245.
49. Ferrajoli A, Manshouri T, Estrov Z, et al. High levels of vascular endothelial gropwth factor receptor-2 correlate with shortened survival in chronic lymphocytic leukemia. Clin Cancer Res. 2001;7:795-799.
50. Kay NE, Bone ND, Tschumper RC, et al. B-CLL cells are capable of synthesis and secretion of both pro- and anti-angiogenic molecules. Leukemia. 2002;16:911-919.
51. Faderl S, Keating MJ, Do KA, et al. Expression profile of 11 proteins and their prognostic significance in patients with chronic lymphocytic leukemia (CLL). Leukemia. 2002;16:1045-1052.
52. Kay NE. The angiogenic status of B-CLL cells B cells: the role of VEGF receptors. Leuk Res. 2004;28:221-222.
53. Bairey O, Boycov O, Kaganovsky E, Zimra Y, Shaklai M, Rabizadeh E. All three receptors for vascular endothelial growth factor (VEGF) are expressed on B-chronic lymphocytic leukemia (CLL) cells. Leuk Res. 2004;28:243-248.
54. Lee YK, Bone ND, Strege AK, Shanafelt TD, Jelinek DF, Kay NE. VEGF receptor phosphorylation status and apoptosis is modulated by a green tea component, epigallocatechin-3-gallate (EGCG), in B-cell chronic lymphocytic leukemia. Blood. 2004;104:788-794.
55. Lee YK, Shanafelt TD, Bone ND, Strege AK, Jelinek DF, Kay NE. VEGF receptors on chronic lymphocytic leukemia (CLL) B cells interact with STAT 1 and 3: implication for apoptosis resistance. Leukemia. 2005;19:513-523.
56. Lopez-Fraga M, Fernandez R, Albar JP, Hahne M. Biologically active APRIL is secreted following intracellular processing in the Golgi apparatus by furin convertase. EMBO Rep. 2001;2:945-951.
57. Wattel E, Preudhomme C, Hecquet B, et al. p53 mutations are associated with resistance to chemotherapy and short survival in hematologic malignancies. Blood. 1994;84:3148-3157.
58. Cordone I, Masi S, Mauro FR, et al. p53 expression in B-cell chronic lymphocytic leukemia: a marker of disease progression and poor prognosis. Blood. 1998;91:4342-4349.
59. Sturm I, Bosanquet AG, Hermann S, Guner D, Dorken B, Daniel PT. Mutation of p53 and consecutive selective drug resistance in B-CLL occurs as a consequence of prior DNA-damaging therapy. Cell Death Differ. 2003;10:477-484.
60. Giles F, Bekele BN, O'Brien S, et al. A prognostic model for survival in chronic lymphocytic leukemia based on p53 espression. Br J Haematol. 2003;121:578-585.
61. Ghia P, Caligaris-Cappio F. The indisplensable role of microenvironment in the natural history of low-grade B-cell neoplasms. Adv Cancer Res. 2000;79:157-173.
62. Ghia P, Granziero L, Chilosi M, Caligaris-Cappio F. Chronic B cell malignancies and bone marrow microenvironment. Semin Cancer Biol. 2002;12:149-155.
63. Pederson IM, Kitada S, Leoni LM, et al. Protection of CLL B cells by a follicular dendritic cell line is dependent on induction of Mcl-1. Blood. 2002;100:1795-1801.
64. Cuni S, Perez-Aciego P, Perez-Chacon G, et al. A sustained activation of PI3K/NF-kappaB pathway is critical for the survival of chronic lymphocytic leukemia B cells. Leukemia. 2004;18:1391-1400.
65. Munk Pederson I, Reed J. Microenvironmental interactions and survival of CLL B-cells. Leuk Lymphoma. 2004;45:2365-2372.
66. Reimold AM, Iwakoshi NN, Manis J, et al. Plasma cell differentiation requires the transcription factor XBP-1. Nature. 2001;412:300-307.
67. Calfon M, Zeng H, Urano F, et al. IRE1 couples endoplasmic reticulum overload to secretory capacity by processing XBP-1 mRNA. Nature. 2002;415:92-96.
68. Zhang K,Wong HN, Song B, Miller CN, Scheuner D, Kaufman RJ. The unfolded protein response sensor IRE1a is required at 2 distinct steps in B cell lymphopoiesis. J Clin Invest. 2005;115:268-281.
69. Iwakoshi NN, Lee AH, Vallabbajosyula P, Otipoby KL, Rajewsky K, Glimcher LH. Plasma cell differentation and the unfolded protein response intersect at the transcription factor XBP-1. Nat Immunol. 2003;4:321-329.
70. Maag RS, Mancini M, Rosen A, Machamer CE. Caspase-resistant golgin-160 disrupts apoptosis induced by secretory pathway stress and ligation of death receptors. Mol Biol Cell. 2005;16:3019-3027.
71. Jones SJ, Ledgerwood EC, Prins JB, et al. TNF recruits TRADD to the plasma membrane but not the trans-Golgi network, the prinicipal subcellular location of TNF-R1. J Immunol. 1999;162:1042-1048.
72. Zhang XD, Franco AV, Nguyen T, Gray CP, Hersey P. Differential localization and regulation of death and decoy receptors for TNF-related apoptosis-inducing ligand (TRAIL) in human melanoma cells. J Immunol. 2000;164:3961-3970.
73. Storey H, Stewart A, Vandenabeele P, Luzio JP. The p55 tumour necrosis factor receptor TNFR1 contains a trans-Golgi network localization signal in the C-terminal region of its cytoplasmic tail. Biochem J. 2002;366:15-22.
74. Shao RG, Shimizu T, Pommier Y. Brefeldin A is a potent inducer of apoptosis in human cancer cells independently of p53. Exp Cell Res. 1996;227:190-196.
75. Pommepuy I, Terro F, Petit B, et al. Brefeldin A induces apoptosis and cell cycle blockade in glioblastoma cell lines. Oncology. 2003;64:459-467.
76. Guo H, Tittle TV, Allen H, Maziarz RT. Brefeldin A-mediated apoptosis requires the activation of caspases and is inhibited by Bcl-2. Exp Cell Res. 1998;245:57-68.
77. Contreras JL, Smyth CA, Bilbao G, et al. Coupling endoplasmic reticulum stress to cell death program in isolated human pancreatic islets: effects of gene transfer of Bcl-2. Transpl Int. 2003;16:537-542.
78. Novak AJ, Bram RJ, Kay NE, Jelinek DF. Aberrant expression of B-lymphocyte stimulator by B chronic lymphocytic leukemia cells: a mechanism for survival. Blood. 2002;100:2973-2979.
79. Kern C, Cornuel J-F, Billard C, et al. Involvement of BAFF and APRIL in the resistance to apoptosis of B-CLL through an autocrine pathway. Blood. 2004;103:679-688.
80. Planelles L, Carvatho-Pinto CE, Hardenberg G, et al. APRIL promotes B-1 cell-associated neoplasm. Cancer Cell. 2004;6:399-408.
81. Kay NE, Wasil T. Survival of chronic lymphocytic leukemia cells: CD40L and the vascular endothelial growth factor (VEGF) connection. Leukemia. 2005;19:531-532.
82. Farahani M, Trewecke AT, Toh CH, et al. Autocrine VEGF mediates the antiapoptotic effect of CD154 on CLL cells. Leukemia. 2005;19:524-530.
83. Anether G, Tinhofer I, Senfter M, Greil R. Tetrocarcin-A-induced ER stress mediates apoptosis in B-CLL cells via a bcl-2-independent pathway. Blood. 2003;101:4561-4568.